Breast Cancer Therapeutics Market size is expected to grow at a CAGR of 12.9% during the forecast period and the market size is expected to reach nearly US$ 79.43 Bn. by 2029.
Breast Cancer Therapeutics Market Dynamics:The key drivers in the market growth includes an increase in adoption of therapeutics pertaining to factors such as the risk of distant reappearance, blocking estrogen from binding to tumor cells and risk of developing the disease in another breast. The industry size is expected to be driven by a rise in western lifestyle adoption, increase in awareness regarding breast cancer, rising prevalence of obesity in women post menopause and short breastfeeding timeframe.To know about the Research Methodology:-Request Free Sample Report Targeted drug therapy held the highest share in the Global Breast Cancer Therapeutics Market in 2021. Targeted drug therapy is expected to lead the growth in the coming years because of factors like stopping the growth of new blood vessels, triggering immune system and changing proteins. Chemotherapy segment is expected to see low growth because of the increased cost associated with drugs that put a financial burden on the patient and reactions of chemotherapy resulting in multi-drug resistance.
Breast Cancer Therapeutics Market Regional Insights:The USA had the largest share in the Global Breast Cancer Therapeutics Market in 2021 due to increased awareness and increased funding in Research and Development. Poland market is expected to grow with the highest CAGR over the forecast period. The Asia Pacific will grow at a substantial pace pertaining to factors like increasing cases of the disease, western lifestyle becoming popular and adoption of advanced technology. Rise in Research and Development funding for innovative drugs, high frequency of CSR activities carried out by corporates for awareness of breast cancer, mergers and acquisition are the key driving factors for the Global Breast Cancer Therapeutics Market over the forecast period.
Breast Cancer Therapeutics Market Research Methodology:Bloomberg, Factiva, and Hoovers are some of the sites that are being referred to gain insights about Global Breast Cancer Therapeutics Market. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Breast Cancer Therapeutics Market globally.
Breast Cancer Therapeutics Market Key Highlights:• Global Breast Cancer Therapeutics Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Breast Cancer Therapeutics Market • Global Breast Cancer Therapeutics Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Global Breast Cancer Therapeutics Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Global Breast Cancer Therapeutics Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Breast Cancer Therapeutics Market are also profiled.
Breast Cancer Therapeutics Market Key Highlights:• Overview of key market forces driving market growth • Comprehensive analyses of technological advancements and market trends • Complete analyses of market competition dynamics • Competitors Strategy Analysis • Graphical and SWOT analysis of industry segments • Up-to-date analyses of industry trends • Well-defined technological growth map
Key Target Audience:• Breast Cancer Treatment Drugs Manufacturers • Group Purchase Organizations (GPOs) • Distributors of Breast Cancer Drugs • Hospitals and Clinics • Healthcare Institutions • Research Institutes • Market Research and Consulting Firms
Years considered to estimate the market size of the Global Breast Cancer Therapeutics Market are as follows:• Base year - 2021 • Estimated year - 2022 • Forecast period - 2022 to 2029
Breast Cancer Therapeutics Market Scope: Inquire before buyingResearch report categorizes the Global Breast Cancer Therapeutics Market-based drug class, technology, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Global Breast Cancer Therapeutics Market with key developments in companies and market trends.
Global Breast Cancer Therapeutics Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 30.09 Bn. Forecast Period 2022 to 2029 CAGR: 12.9% Market Size in 2029: US $ 79.43 Bn. Segments Covered: by Drug Class • HER2 Inhibitors • Mitotic Inhibitors • Anti-metabolites • Aromatase Inhibitors • Hormone Receptor Agonist/Antagonist by Technology • Chemotherapy o Alkylating Agents o Cytotoxic agents o Antimetabolites o Plant derivatives o Others• Radiation Therapy o Intraoperative radiotherapy, o External beam radiation therapy o Brachytherapy o Radioisotope therapy• Hormone Therapy o Hormone Antagonists o Corticosteroids o Aromatase inhibitor o Selective estrogen receptor modulators (SERMs)• Biotherapy o Monoclonal antibodies o Interleukin o Kinases o Others
Breast Cancer Therapeutics Market, by Region• North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)
Breast Cancer Therapeutics Market, Key Players are:• AstraZeneca • Eisai Co., Ltd • Eli Lilly • Roche Diagnostics • Novartis AG • Pfizer • Celgene • Sanofi • Teva Pharmaceutical • Bristol-Myers Squibb Co. • Merck & Co. Inc. • Medivation Inc. • GlaxoSmithKline Plc. • F. Hoffmann-La Roche Ltd. • Puma Biotechnology • Genentech • Fresenius kabi • AbbVie, Inc. • Johnson & Johnson • Astellas Pharma, Inc. • Bayer AG • Takeda Pharmaceutical Company Limited Frequently Asked Questions: 1. Which region has the largest share in Global Breast Cancer Therapeutics Market? Ans: Asia Pacific region holds the highest share in 2021. 2. What is the growth rate of Global Breast Cancer Therapeutics Market? Ans: The Global Breast Cancer Therapeutics Market is growing at a CAGR of 12.9% during forecasting period 2022-2029. 3. What is scope of the Global Breast Cancer Therapeutics market report? Ans: Global Breast Cancer Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Breast Cancer Therapeutics market? Ans: The important key players in the Global Breast Cancer Therapeutics Market are – AstraZeneca, Eisai Co., Ltd, Eli Lilly, Roche Diagnostics, Novartis AG, Pfizer, Celgene, Sanofi, Teva Pharmaceutical, Bristol-Myers Squibb Co., Merck & Co. Inc., Medivation Inc., GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Puma Biotechnology, Genentech, Fresenius kabi, AbbVie, Inc., Johnson & Johnson, Astellas Pharma, Inc., Bayer AG, and Takeda Pharmaceutical Company Limited 5. What is the study period of this market? Ans: The Global Breast Cancer Therapeutics Market is studied from 2021 to 2029.
1. PREFACE 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 2. EXECUTIVE SUMMARY 2.1 Global Breast Cancer Therapeutics: Market Snapshot 2.2 Global Breast Cancer Therapeutics Market Share, by Geography 2.3 Global Breast Cancer Therapeutics Market, by Drug type 2.4 Global Breast Cancer Therapeutics Market Share, by Technology 3. GLOBAL BREAST CANCER THERAPEUTICS MARKET OVERVIEW 3.1 Market Definition and Overview 3.2 Epidemiology & High Risk Groups 3.3 Diagnosis and Types of Breast Cancer 3.4 Other Breast Cancer Therapies 3.5 Market Dynamics 3.5.1 Drivers 220.127.116.11 Higher Incidence Rate 18.104.22.168 Demographic Transition 22.214.171.124 Rising Prevalence Of Obesity 126.96.36.199 Diagnostic Screening Programs 188.8.131.52 Increase in Private Health Insurance Plans: 3.5.2 Restraints 184.108.40.206 Generic Drugs: Substitute Branded Drugs 220.127.116.11 Intense Competition: Fall in Prices 18.104.22.168 Access barriers due to high drug costs 22.214.171.124 Absence of Social Health Insurance 126.96.36.199 Serious Side Effects of Breast Cancer Therapeutics 188.8.131.52 Countries Lacking Women Empowerment 184.108.40.206 Newer medication options 3.5.3 Opportunities 220.127.116.11 Potential Growth of Domestic Pharmaceutical Companies 18.104.22.168 Combination Drug Therapy 22.214.171.124 Technological Advancements and Robust Trends of Drug Approval 126.96.36.199 New Companion Diagnostics Models 188.8.131.52 Drug Therapy for Triple Negative (TNBC) 184.108.40.206 Approval for Multiple Indications (positive & negative types) HER2 breast cancer 3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography 3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players 4. GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY DRUG CLASS 4.1 Overview 4.2 Global HER2 Inhibitors Market Revenue 4.2.1 Herceptin (Trastuzumab) 4.2.2 Tykerb (Lapatinib) 4.2.3 Perjeta (Pertuzumab) 4.2.4 Kadcyla (Ado-trastuzumab emtansine) 4.3 Global Mitotic Inhibitors Market Revenue 4.3.1 Halaven (Eribulin) 4.3.2 Taxotere (Docetaxel) 4.3.3 Ixempra (Ixabepilone) 4.4 Global Anti-metabolites Market Revenue 4.4.1 Gemzar (Gemcitabine) 4.5 Global Aromatase Inhibitors Market Revenue 4.5.1 Femara (Leterozole) 4.5.2 Aromasin (Exemestane) 4.5.3 Arimidex (Anastrozole) 4.5.4 Ibrance (Palbociclib) 4.5.5 Afinitor (Everolimus) 4.6 Global Hormone Receptor Market Revenue 4.6.1 Zoladex 4.6.2 Faslodex 4.6.3 Fareston 5. GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY TECHNOLOGY 5.1 Chemotherapy 5.1.1Alkylating Agents 5.1.2Cytotoxic agents 5.1.3Antimetabolites 5.1.4Plant derivatives 5.1.5Others 5.2 Radiation Therapy 5.2.1Intraoperative radiotherapy, 5.2.2 External beam radiation therapy 5.2.3 Brachytherapy 5.2.4 Radioisotope therapy 5.3 Hormone Therapy 5.3.1Hormone antagonists 5.3.2 Corticosteroids 5.3.3 Aromatase inhibitor 5.3.4 Selective estrogen receptor modulators (SERMs) 5.4 Biotherapy 5.4.1 Monoclonal antibodies 5.4.2 Interleukin 5.4.3 Kinases 5.4.4Others 6. GLOBAL BREAST CANCER THERAPEUTICS MARKET, BY GEOGRAPHY 6.1 Introduction 6.2 North America 6.2.1 U.S. 6.2.2 Canada 6.3 Europe 6.3.1 Germany 6.3.2 France 6.3.3 U.K. 6.3.4 Italy 6.3.5 Spain 6.3.6 Russia 6.3.7 Rest of Europe (RoE) 6.4 Asia-Pacific (APAC) 6.4.1 Japan 6.4.2 China 6.4.3 India 6.4.4 Rest of Asia-Pacific (RoAPAC) 6.5 Latin America 6.5.1 Brazil 6.5.2 Argentina 6.5.3 Rest of Latin America (RoLA) 6.6 Middle East and Africa 7. COMPETITIVE LANDSCAPE 7.1 Overview 7.2 Market Share Analysis 7.3 Competitive Situation and Trends 7.4 New Product Launches 7.5 Agreements, Partnerships, and Collaborations 7.6 Acquisitions 7.7 Expansions 7.8 Other Strategies 8. COMPANY PROFILES 8.1 AstraZeneca plc 8.2 Eisai Co., Ltd. 8.3 Eli Lilly and Company 8.4 F. Hoffmann-La Roche Ltd. 8.5 GlaxoSmithKline plc 8.6 Novartis International AG 8.7 Pfizer, Inc. 8.8 Puma Biotechnology, Inc. 8.9 Sanofi S.A. 8.10 Teva Pharmaceutical Industries Ltd. 8.11 Genentech 8.12 Fresenius kabi 8.13 AbbVie, Inc. 8.14 Johnson & Johnson 8.15 Astellas Pharma, Inc. 8.16 Bayer AG 8.17 Takeda Pharmaceutical Company Limited